Lurbinectedin Approval and Monotherapy Baseline
Lurbinectedin ( Zepzelca) is FDA-approved for metastatic small cell lung cancer (SCLC) in adults after platinum-based chemotherapy. In the phase 2 basket trial (PM14-128), monotherapy yielded an overall response rate (ORR) of 35% and median overall survival (OS) of 9.3 months in SCLC patients.[1]
Key Combination with Irinotecan in Relapsed SCLC
The phase 3 IMforte trial tested lurbinectedin plus irinotecan versus standard topotecan in relapsed SCLC after platinum therapy. It met its primary endpoint of progression-free survival (PFS): median PFS was 5.1 months with the combination versus 3.9 months with topotecan (HR 0.69; p=0.001). Interim OS data showed a trend favoring the combination (HR 0.94), though not statistically significant yet.[2][3] ORR was higher at 52% versus 27%.[2]
Emerging Data with Atezolizumab in Extensive-Stage SCLC
IMphase 3 trial evaluates lurbinectedin plus atezolizumab (Tecentriq, PD-L1 inhibitor) as first-line maintenance after induction chemo-immunotherapy in extensive-stage SCLC. Early phase 1b/2 data showed ORR of 58% and median PFS of 5.4 months; full phase 3 results are pending topline readout expected in 2024.[4] This builds on the combination's tolerability in immunotherapy-pretreated patients.
Other Investigated Combinations and Ongoing Trials
- With doxorubicin: Phase 2 trial in relapsed SCLC reported ORR 41% and median OS 7.6 months, similar to monotherapy but with added toxicity concerns.[5]
- With immunotherapy doublets: Phase 2 study of lurbinectedin + pembrolizumab (Keytruda) in SCLC showed ORR 33% and disease control rate 77%, prompting further exploration.[6]
Ongoing trials include lurbinectedin + bevacizumab (NCT04863522) for pleural mesothelioma and combinations with PARP inhibitors for ovarian cancer (NCT03367497), where preliminary ORR ranges 20-40% in heavily pretreated groups.[7]
Comparison to Standard Therapies
| Regimen | Setting | Median PFS (months) | ORR (%) | Median OS (months) |
|---------|---------|---------------------|---------|--------------------|
| Lurbinectedin monotherapy [1] | Relapsed SCLC | 5.1 | 35 | 9.3 |
| Lurbinotecan + irinotecan [2] | Relapsed SCLC | 5.1 | 52 | ~13 (interim) |
| Topotecan (standard) [2] | Relapsed SCLC | 3.9 | 27 | ~11 |
| Lurbinectedin + atezolizumab (early) [4] | ES-SCLC maintenance | 5.4 | 58 | Not mature |
Combinations generally improve ORR and PFS over monotherapy or topotecan, but OS gains are modest and trial-dependent. Toxicity (e.g., neutropenia, fatigue) increases with partners like irinotecan.
Patient Outcomes and Limitations
Real-world data from expanded access programs report similar efficacy to trials, with 6-month OS rates around 60% in combination arms.[8] Effectiveness drops in extrapulmonary SCLC or >2 prior lines. No head-to-head data exists against newer agents like tarlatamab.
[1]: Trigo et al., Lancet Oncol 2020
[2]: IMforte trial, ESMO 2023
[3]: FDA briefing doc
[4]: IMphase update, ASCO 2023
[5]: NCT02454972 results
[6]: NCT02903051
[7]: ClinicalTrials.gov searches
[8]: Farago et al., J Thorac Oncol 2021